Phases, active trials: Phase 1: 37, Phase 2: 11, Phase 3: 43, Other: 41
Novo Nordisk has become one of the most valuable pharmaceutical companies in the world on the strength of its GLP-1 receptor agonist franchise. Ozempic (semaglutide injection) and Rybelsus (semaglutide oral) for type 2 diabetes, and Wegovy (semaglutide 2.4 mg) for obesity, represent a paradigm shift in metabolic disease treatment. The SELECT cardiovascular outcomes trial demonstrated that semaglutide reduces major cardiovascular events in overweight/obese patients without diabetes — transforming the obesity indication from cosmetic to cardiovascular risk reduction. Novo Nordisk's next-generation pipeline includes cagrilintide (amylin analogue), oral GLP-1/GIP combinations, and the GLP-1/GIP/glucagon tri-agonist CagriSema. In rare disease, Novo's Factor VIII (Alhemo), Sogroya (growth hormone), and mim8 (bispecific FVIII mimetic for hemophilia) are advancing through late-stage trials.
- Diabetes (GLP-1, basal insulin, SGLT2)
- Obesity / metabolic disease (semaglutide, dual agonists)
- Cardiovascular outcomes (MACE reduction)
- Rare hematology (hemophilia, rare bleeding disorders)
- Growth disorders / endocrinology
- Ozempic/Wegovy/Rybelsus (semaglutide) — GLP-1 RA, T2D/obesity/CV
- CagriSema — cagrilintide/semaglutide combo, obesity
- Awiqli (once-weekly insulin icodec) — ultra-long-acting basal insulin
- Mim8 — bispecific FVIII mimetic, hemophilia A
- Alhemo (marstacimab) — anti-TFPI, rare bleeding disorders
- IcoSema — insulin icodec/semaglutide fixed-ratio combo
Monitor the Novo Nordisk pipeline daily
Get a daily digest when Novo Nordisk registers new trials or updates existing protocols. Free plan, no credit card required.
Start monitoring free| Condition / indication | Active trials |
|---|---|
| Obesity | 57 |
| Overweight | 32 |
| Diabetes Mellitus, Type 2 | 15 |
| Haemophilia A | 7 |
| Healthy Volunteers | 6 |
| Heart Failure | 6 |
| Type 2 Diabetes | 5 |
| Diabetes Mellitus, Type 1 | 4 |
Novo Nordisk's GLP-1 expansion trials — including semaglutide in NASH/MASH, heart failure, sleep apnea, CKD, and addiction — are generating the highest search interest of any pharma pipeline in 2026. Their next-generation obesity combination trials (CagriSema vs. tirzepatide) are among the most watched competitive programs across pharma BD and investor audiences.
DataLookout monitors ClinicalTrials.gov daily and surfaces changes to Novo Nordisk's registered studies: new trial registrations, status transitions (for example "Not yet recruiting" to "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and day-to-day pipeline developments.
- Sponsor normalization: Novo Nordisk may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
- Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
- Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced, not just new registrations.
- Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
- Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.
Automate your Novo Nordisk pipeline intelligence
Used by pharma BD, strategy, and competitive intelligence professionals. Setup takes under 5 minutes.
Get started free| Trial | Status | Latest tracked change | Seen |
|---|---|---|---|
| A Research Study on How NNC0638-0355, a New Medicine, Works in People Living… NCT06577766 | Active, Not Recruiting | Completion pushed: 2026-09-24 → 2027-10-11 | 2026-08-18 |
| Research Study to Examine Blood Sugar Control, Treatment Satisfaction and… NCT07658417 | Enrolling by Invitation | Enrolling by invitation only | 2026-09-16 |
| Study to Assess Tolerability of Injecting Larger Volumes (2-5 mL)… NCT07769489 | Recruiting | Recruitment opened | 2026-09-16 |
| AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111… NCT07503210 | Active, Not Recruiting | Enrollment closed, study ongoing | 2026-09-12 |
| A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention… NCT07184086 | Active, Not Recruiting | Completion pushed: 2027-10-12 → 2028-02-09 | 2026-09-11 |
Each trial page shows every change DataLookout has recorded for that trial.